Anakinra

Anakinra is a drug used to treat rheumatoid arthritis. It is an interleukin 1 receptor antagonist. It is produced by Swedish Orphan Biovitrum.

Anakinra

Kineret

(7R)-7-{[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-({[(2,2-dimethylpropanoyl)oxy]methoxy}imino)acetyl]amino}-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

• Absorption: The absolute bioavailability is 95%.
• Excretion: Urine

Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. 

100 mg daily take same time every day.

For the treatment of

• NOMID (Neonatal-Onset Multisystem Inflammatory Disease).
• Adult rheumatoid arthritis 

Increased incidence of serious infection, notably neutropenia, Blood dyscrasias, headache, diarrhea, nausea, and abdominal pain.

Coadmin with etanercept may induce serious infection and neutropenia.

Active infections.

Store at 2-8°C subcutaneous injection

Molecular weight

17257.6 Dalton

Molecular formula

C759H1186N208O232S10

CAS number

143090-92-0

Precautions

• Caution when used in patients with chronic infections or immunocompromised patients. 
• Monitor neutrophil counts before initiating treatment, mthly for 3 mth, and quarterly up to 1 yr thereafter.
• Discontinue treatment if patient develops serious infection.
• May increase risk of lymphoma.
• Avoid concurrent usage with TNF blocking agents or live vaccines.